HDAC9 and hepatocellular carcinoma: In a murine hepatocellular carcinoma model, an HDAC inhibitor, belinostat, activated the antitumor action against hepatocellular carcinoma in combination with anti-CTLA-4, while anti-PD-1 therapy could not obtain enough additive effect of the HDAC inhibitor against hepatocellular carcinoma [67].